Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment

Journal of Neurosurgery
David LyDennis C Shrieve

Abstract

BRAF inhibitors improve progression-free and overall survival in patients with metastatic melanoma. Brain metastases are common, and stereotactic radiosurgery (SRS) has been used, resulting in excellent local control. Because BRAF inhibitors are associated with intracranial responses, the authors hypothesized that BRAF inhibitors would improve local control in patients with melanoma who are receiving SRS for brain metastases. The authors retrospectively identified patients with metastatic melanoma who had been tested for BRAF mutation and treated with SRS for brain metastases. Patients with previous resection, multiple brain metastases, or multiple courses of SRS were eligible. SRS was delivered in a single fraction to a median dose of 2000 cGy. Patients with a BRAF mutation were treated with a BRAF inhibitor on the basis of physician preference. The authors identified 52 patients who were treated in 82 treatment sessions for 185 brain metastases and 13 tumor beds. At a median follow-up of 10.5 months, the 1-year local control rate was 69.2%. At 1 year, the local control rate for brain metastases in patients with BRAF mutation with BRAF treatment was 85.0%, and the local control rate for brain metastases in those without BRAF t...Continue Reading

References

Jun 18, 2002·Nature·Helen DaviesP Andrew Futreal
Jun 23, 2004·Oncogene·Maria KarasaridesRichard Marais
Jul 6, 2004·International Journal of Radiation Oncology, Biology, Physics·Ugur SelekMoshe H Maor
Jun 18, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Yue CaoTheodore S Lawrence
Jun 21, 2008·International Journal of Radiation Oncology, Biology, Physics·Lisa J HazardDennis C Shrieve
Nov 17, 2009·Proceedings of the National Academy of Sciences of the United States of America·Caroline M EmeryLevi A Garraway
Jun 8, 2010·Journal of Neurosurgery·Donald N LiewL Dade Lunsford
Feb 8, 2011·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Maria J SambadeJaniel M Shields
Jun 7, 2011·The New England Journal of Medicine·Paul B ChapmanUNKNOWN BRIM-3 Study Group
Oct 14, 2011·Chinese Journal of Integrative Medicine·Jin XiongGuang-Ying Huang
Nov 2, 2011·Journal of the American Academy of Dermatology·Ahmedin JemalPhyllis A Wingo
Mar 29, 2012·The Journal of Pharmacology and Experimental Therapeutics·Rajendar K MittapalliWilliam F Elmquist
Aug 1, 2012·World Journal of Surgical Oncology·Elisa CastellaniGiuseppe Noya
Oct 2, 2012·The New England Journal of Medicine·Keith T FlahertyJeffrey Weber
Mar 27, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Imke SatzgerRalf Gutzmer
Apr 13, 2013·Journal of Neuro-oncology·Ashwatha NarayanaAnna C Pavlick
May 8, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christopher J AnkerKenneth F Grossmann
May 17, 2013·JAMA Dermatology·Andrea ForschnerFriedegund Meier
May 24, 2013·JAMA Dermatology·Lise BoussemartCaroline Robert
Sep 26, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Natalia RompotiLisa Zimmer
Nov 7, 2013·European Journal of Dermatology : EJD·Lucie PeuvrelBrigitte Dreno
Dec 4, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Reinhard DummerJeannine D Rinderknecht

❮ Previous
Next ❯

Citations

May 22, 2016·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·R RauschenbergF Meier
Oct 30, 2016·International Journal of Radiation Oncology, Biology, Physics·John P KirkpatrickHelen A Shih
Mar 10, 2017·Expert Review of Anticancer Therapy·Elisabetta TrinoAndrea Riccardo Filippi
Oct 19, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A V TalletY M Kirova
Feb 17, 2018·Therapeutic Advances in Medical Oncology·Rodica Di Lorenzo, Manmeet S Ahluwalia
Oct 5, 2019·International Journal of Cancer. Journal International Du Cancer·Mark P van OpijnenEllen H W Kapiteijn
Apr 10, 2020·Journal of Neurosurgical Sciences·Boryana M EastmanJerome J Graber
Jun 25, 2020·Cancers·Paolo BeccoMassimo Aglietta
Sep 3, 2020·Nature Reviews. Neurology·Riccardo SoffiettiRoberta Rudà
May 6, 2020·Radiation Oncology·Rosario MazzolaFilippo Alongi
Jan 26, 2016·Current Opinion in Oncology·Simone M GoldingerPaul Nathan
May 8, 2016·BJR Case Reports·Daniela AlterioBarbara Alicja Jereczek-Fossa
Jul 19, 2021·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·M Le Guyader, D Antoni
May 17, 2021·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·K A KesselS E Combs

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01378975

Software Mentioned

StatsDirect

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved